Cargando…
Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial
OBJECTIVES: We conducted a single-blinded, randomized trial to evaluate the safety, reactogenicity, and immunogenicity of heterologous booster vaccination in health care workers (HCW) who had received two doses of ChAdOx1 nCov-19. METHODS: HCW who had at least 90 days after the second dose were enro...
Autores principales: | Chuang, Chih-Hsien, Huang, Chung-Guei, Huang, Ching-Tai, Chen, Yi-Ching, Kung, Yu-An, Chen, Chih-Jung, Chuang, Tzu-Chun, Liu, Ching-Chi, Huang, Po-Wei, Yang, Shu-Li, Gu, Po-Wen, Shih, Shin-Ru, Chiu, Cheng-Hsun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651991/ https://www.ncbi.nlm.nih.gov/pubmed/36399969 http://dx.doi.org/10.1016/j.jcv.2022.105328 |
Ejemplares similares
-
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
por: Chen, Chih-Jung, et al.
Publicado: (2022) -
ChAdOx1 nCov-19 vaccine-induced thrombotic thrombocytopenic purpura successfully treated with plasmapheresis
por: Wang, Yen-Ching, et al.
Publicado: (2021) -
Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021) -
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022) -
Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)